

# Nicolino Ruperto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1632690/publications.pdf>

Version: 2024-02-01

303  
papers

22,848  
citations

8208

78  
h-index

10399

144  
g-index

312  
all docs

312  
docs citations

312  
times ranked

11169  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 798-806.	0.5	1,073
2	Preliminary definition of improvement in juvenile arthritis. <i>Arthritis and Rheumatism</i> , 1997, 40, 1202-1209.	6.7	922
3	Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 2385-2395.	13.9	716
4	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. <i>Arthritis Care and Research</i> , 2011, 63, 465-482.	1.5	658
5	Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 2396-2406.	13.9	588
6	Development and validation of a composite disease activity score for juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 658-666.	6.7	579
7	Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2008, 359, 810-820.	13.9	530
8	Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. <i>Lancet, The</i> , 2008, 372, 383-391.	6.3	486
9	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2016, 68, 566-576.	2.9	427
10	Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2004, 31, 2290-4.	1.0	419
11	American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 929-936.	1.5	391
12	A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3096-3106.	6.7	373
13	Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Journal of Pediatrics</i> , 2005, 146, 598-604.	0.9	365
14	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 678-685.	0.5	350
15	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 481-489.	0.5	338
16	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, 3160-3169.	2.9	322
17	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. <i>Journal of Rheumatology</i> , 2019, 46, 190-197.	1.0	318
18	Localized scleroderma in childhood is not just a skin disease. <i>Arthritis and Rheumatism</i> , 2005, 52, 2873-2881.	6.7	308

#	ARTICLE	IF	CITATIONS
19	A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. <i>Arthritis and Rheumatism</i> , 2004, 50, 2191-2201.	6.7	307
20	Classification criteria for autoinflammatory recurrent fevers. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1025-1032.	0.5	300
21	Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (Câ€HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SFâ€36), Child Health Questionnaire (CHO), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle T. <i>Arthritis Care and Research</i> , 2011, 63, S118-57.	1.5	288
22	The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2160-2167.	0.5	256
23	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1110-1117.	0.5	251
24	Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1906.	3.8	242
25	Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirtyâ€eight patients. <i>Arthritis and Rheumatism</i> , 2009, 60, 3388-3399.	6.7	231
26	Methotrexate Withdrawal at 6 vs 12 Months in Juvenile Idiopathic Arthritis in Remission&lt;sub&gt;title&gt;A Randomized Clinical Trial&lt;/sub&gt;. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1266.	3.8	229
27	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 799-805.	0.5	215
28	Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. <i>British Journal of Rheumatology</i> , 2003, 42, 1452-1459.	2.5	209
29	Longâ€term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. <i>Arthritis Care and Research</i> , 2010, 62, 63-72.	1.5	207
30	Longâ€term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1792-1802.	6.7	204
31	International consensus on preliminary definitions of improvement in adult and juvenile myositis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2281-2290.	6.7	202
32	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 790-797.	0.5	187
33	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2018-213030.	0.5	183
34	Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2043-2049.	0.5	180
35	Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. <i>Arthritis and Rheumatism</i> , 2012, 64, 2366-2374.	6.7	171
36	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. <i>Arthritis and Rheumatology</i> , 2016, 68, 2795-2805.	2.9	168

#	ARTICLE	IF	CITATIONS
37	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. <i>Lancet, The</i> , 2016, 387, 671-678.	6.3	168
38	A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. <i>Arthritis and Rheumatism</i> , 2012, 64, 557-567.	6.7	167
39	The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 57, 203-212.	6.7	164
40	A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report. <i>Journal of Rheumatology</i> , 2011, 38, 938-953.	1.0	159
41	An International registry on Autoinflammatory diseases: the Eurofever experience. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1177-1182.	0.5	158
42	Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study. <i>Arthritis and Rheumatism</i> , 2003, 49, 501-507.	6.7	150
43	International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 2005, 52, 2607-2615.	6.7	146
44	Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). <i>Archives of Disease in Childhood</i> , 2011, 96, 596-601.	1.0	143
45	Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 2092-2102.	6.7	142
46	An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 764-768.	1.0	140
47	Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 267-275.	6.7	140
48	The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/european League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study. <i>Arthritis and Rheumatism</i> , 2008, 59, 4-13.	6.7	136
49	A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 2989-2996.	6.7	133
50	Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 718-722.	0.5	129
51	Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort study. <i>Arthritis and Rheumatism</i> , 2007, 57, 35-43.	6.7	121
52	Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2168-2173.	0.5	120
53	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 255-263.	2.7	120
54	Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1534-1541.	1.0	119

#	ARTICLE	IF	CITATIONS
55	Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Three-Variable Juvenile Arthritis Disease Activity Score. <i>Arthritis Care and Research</i> , 2014, 66, 1703-1709.	1.5	115
56	Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1558-1565.	0.5	114
57	Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1083-1090.	0.5	113
58	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 686-693.	0.5	109
59	Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1114-1122.	0.5	106
60	Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1340-1348.	0.5	106
61	Follow-Up and Quality of Life of Patients with Cryopyrin-Associated Periodic Syndromes Treated with Anakinra. <i>Journal of Pediatrics</i> , 2010, 157, 310-315.e1.	0.9	105
62	The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. <i>Rheumatology</i> , 2018, 57, 1203-1211.	0.9	105
63	Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1991-1997.	0.5	103
64	Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. <i>Arthritis and Rheumatology</i> , 2016, 68, 218-228.	2.9	103
65	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2871-2880.	2.9	101
66	Update on outcome assessment in myositis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 303-318.	3.5	100
67	Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 1120-1127.	6.7	98
68	Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 21-29.	0.5	96
69	Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 913-920.	6.7	95
70	Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. <i>Arthritis and Rheumatism</i> , 2004, 51, 458-464.	6.7	93
71	Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 662-667.	0.5	92
72	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 792-801.	0.5	92

#	ARTICLE	IF	CITATIONS
73	Juvenile idiopathic arthritis. <i>Nature Reviews Disease Primers</i> , 2022, 8, 5.	18.1	90
74	International research networks in pediatric rheumatology: the PRINTO perspective. <i>Current Opinion in Rheumatology</i> , 2004, 16, 566-570.	2.0	87
75	Clinical features of childhood granulomatosis with polyangiitis (wegenerâ€™s granulomatosis). <i>Pediatric Rheumatology</i> , 2014, 12, 18.	0.9	85
76	Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 38-41.	0.5	84
77	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. <i>Arthritis Care and Research</i> , 2010, 62, 1533-1541.	1.5	84
78	Correlation between conventional disease activity measures in juvenile chronic arthritis. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 197-200.	0.5	83
79	Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3087-3095.	6.7	80
80	A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: Short- and long-term efficacy and safety results. <i>Arthritis and Rheumatism</i> , 2005, 52, 563-572.	6.7	79
81	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1710-1719.	0.5	79
82	Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. <i>Lancet, The</i> , 2021, 398, 1984-1996.	6.3	79
83	Outcome in juvenile onset systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2005, 17, 568-573.	2.0	77
84	The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity core set. <i>Arthritis and Rheumatism</i> , 2005, 52, 2854-2864.	6.7	77
85	Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1380-1383.	0.5	77
86	Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. <i>Rheumatology International</i> , 2018, 38, 5-17.	1.5	74
87	Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1357-1362.	0.5	74
88	The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvement. <i>Arthritis and Rheumatism</i> , 2006, 55, 355-363.	6.7	72
89	Abatacept improves healthâ€™related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2010, 62, 1542-1551.	1.5	72
90	Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 856-863.	1.0	72

#	ARTICLE	IF	CITATIONS
91	Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. <i>Clinical and Experimental Immunology</i> , 2015, 181, 385-400.	1.1	72
92	Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. <i>Arthritis Research and Therapy</i> , 2018, 20, 285.	1.6	71
93	Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2006, 55, 177-183.	6.7	70
94	Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. <i>Pediatric Rheumatology</i> , 2012, 10, 39.	0.9	70
95	Long-term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years. <i>Arthritis and Rheumatology</i> , 2015, 67, 2759-2770.	2.9	64
96	Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. <i>Pediatric Rheumatology</i> , 2017, 15, 86.	0.9	64
97	Catch-up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial. <i>Arthritis and Rheumatology</i> , 2015, 67, 840-848.	2.9	63
98	Use of the sharp and larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2006, 55, 717-723.	6.7	61
99	Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 440-446.	0.5	60
100	Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 994-1001.	1.0	59
101	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 911-923.	2.9	59
102	The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. <i>Journal of Pediatrics</i> , 1999, 135, 316-320.	0.9	57
103	Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designs. <i>Arthritis and Rheumatism</i> , 2010, 62, 3131-3139.	6.7	57
104	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000161.	1.8	57
105	Measures of disease activity and damage in paediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). <i>Arthritis Care and Research</i> , 2011, 63, S112-7.	1.5	55
106	A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 511-517.	0.5	55
107	A national cohort study on pediatric Behçet's disease: cross-sectional data from an Italian registry. <i>Pediatric Rheumatology</i> , 2017, 15, 84.	0.9	55
108	Assessing current outcomes of juvenile idiopathic arthritis: A cross-sectional study in a tertiary center sample. <i>Arthritis and Rheumatism</i> , 2008, 59, 1571-1579.	6.7	52

#	ARTICLE	IF	CITATIONS
109	Performance of Different Diagnostic Criteria for Familial Mediterranean Fever in Children with Periodic Fevers: Results from a Multicenter International Registry. <i>Journal of Rheumatology</i> , 2016, 43, 154-160.	1.0	52
110	Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. <i>Lancet, The</i> , 2017, 389, 909-916.	6.3	52
111	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 898-910.	2.9	52
112	Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 677-686.	1.5	52
113	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 167.	1.2	52
114	Biological classification of childhood arthritis: roadmap to a molecular nomenclature. <i>Nature Reviews Rheumatology</i> , 2021, 17, 257-269.	3.5	52
115	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 782-791.	0.5	51
116	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. <i>Journal of Pediatrics</i> , 2017, 189, 72-78.e3.	0.9	50
117	A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). <i>Archives of Disease in Childhood</i> , 2012, 97, 185-188.	1.0	49
118	Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. <i>Arthritis Research and Therapy</i> , 2017, 19, 13.	1.6	49
119	Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: An international multicenter PRINTO study. <i>Arthritis and Rheumatism</i> , 2011, 63, 3142-3152.	6.7	47
120	Validation of Relapse Risk Biomarkers for Routine Use in Patients With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 949-955.	1.5	47
121	Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1479-1483.	0.5	46
122	Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 816-824.	1.0	46
123	Health-related quality of life of patients with juvenile dermatomyositis: Results from the paediatric rheumatology international trials organisation multinational quality of life cohort study. <i>Arthritis and Rheumatism</i> , 2009, 61, 509-517.	6.7	45
124	Subcutaneous Abatacept in Patients With Polyarticular-course Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1144-1154.	2.9	45
125	Consensus procedures and their role in pediatric rheumatology. <i>Current Rheumatology Reports</i> , 2008, 10, 142-146.	2.1	44
126	Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1405-1411.	0.5	44



#	ARTICLE	IF	CITATIONS
127	Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept. <i>Journal of Rheumatology</i> , 2013, 40, 192-200.	1.0	43
128	The Eurofever Project: towards better care for autoinflammatory diseases. <i>European Journal of Pediatrics</i> , 2011, 170, 445-452.	1.3	41
129	Preliminary definition of improvement in juvenile arthritis. <i>Arthritis and Rheumatism</i> , 1997, 40, 1202-1209.	6.7	40
130	Development and Testing of Reduced Joint Counts in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 183-190.	1.0	40
131	A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2010, 49, 1272-1280.	0.9	39
132	Advances from clinical trials in juvenile idiopathic arthritis. <i>Nature Reviews Rheumatology</i> , 2013, 9, 557-563.	3.5	39
133	Current and future perspectives in the management of juvenile idiopathic arthritis. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 360-370.	2.7	39
134	Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. <i>Rheumatology</i> , 2020, 59, 3505-3514.	0.9	39
135	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 907-921.	0.5	38
136	MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 363-368.	0.5	36
137	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. <i>Pediatric Rheumatology</i> , 2016, 14, 68.	0.9	35
138	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. <i>Journal of Rheumatology</i> , 2019, 46, 1006-1013.	1.0	34
139	Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 117-24.	0.4	34
140	Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2008, 59, 1112-1119.	6.7	33
141	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria—methodological aspects. <i>Rheumatology</i> , 2017, 56, 1884-1893.	0.9	33
142	Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score—Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1966-1975.	2.9	33
143	Juvenile idiopathic arthritis and malignancy. <i>Rheumatology</i> , 2014, 53, 968-974.	0.9	32
144	Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. <i>Arthritis Research and Therapy</i> , 2019, 21, 125.	1.6	31

#	ARTICLE	IF	CITATIONS
145	Physicians' and parents' ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1773-6.	1.0	30
146	Impact of the European paediatric legislation in paediatric rheumatology: past, present and future. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1893-1896.	0.5	29
147	Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 1621-1629.	1.5	28
148	Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind. <i>Clinical Rheumatology</i> , 2019, 38, 563-575.	1.0	28
149	Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 488-493.	6.7	27
150	Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey. <i>Pediatric Rheumatology</i> , 2010, 8, 29.	0.9	27
151	Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 1262-1270.	1.5	27
152	A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. <i>Pediatric Rheumatology</i> , 2017, 15, 31.	0.9	27
153	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. <i>Arthritis Research and Therapy</i> , 2020, 22, 71.	1.6	25
154	Criteria to define response to therapy in paediatric rheumatic diseases. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 125-131.	0.8	24
155	Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 401-406.	0.5	23
156	Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 336-346.	2.9	23
157	Clinical assessment in juvenile dermatomyositis. <i>Autoimmunity</i> , 2006, 39, 197-203.	1.2	22
158	Emerging drugs to treat juvenile idiopathic arthritis. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 493-505.	1.0	22
159	An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphthous stomatitis pharyngitis cervical adenitis (PFAPA). <i>Pediatric Rheumatology</i> , 2018, 16, 27.	0.9	21
160	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 2147-2158.	2.9	21
161	The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. <i>Pediatric Rheumatology</i> , 2010, 8, 24.	0.9	20
162	Current Medical Treatments for Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , 2011, 2, 60.	1.6	20

#	ARTICLE	IF	CITATIONS
163	American College of Rheumatology Provisional Criteria for Global Flares in Childhood Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 813-822.	1.5	19
164	Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. <i>Arthritis Care and Research</i> , 2018, 70, 1312-1319.	1.5	19
165	IgA Nephropathy and Henoch-Schönlein Syndrome Occurring in the Same Patient. <i>Nephron</i> , 1996, 72, 111-112.	0.9	18
166	Treatment of juvenile idiopathic arthritis: what's new?. <i>Current Opinion in Rheumatology</i> , 2019, 31, 428-435.	2.0	18
167	Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021, 60, 4568-4580.	0.9	18
168	JIA, treatment and possible risk of malignancies. <i>Nature Reviews Rheumatology</i> , 2011, 7, 6-7.	3.5	17
169	Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. <i>Arthritis Care and Research</i> , 2020, 72, 1420-1430.	1.5	17
170	Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1673-1682.	2.9	17
171	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. <i>Journal of Rheumatology</i> , 2019, 46, 429-436.	1.0	16
172	INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 783-791.e4.	2.0	16
173	Efficacy and Safety of Tocilizumab for Polyarticular Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 530-541.	2.9	16
174	A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofen lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians. <i>Italian Journal of Pediatrics</i> , 2011, 37, 48.	1.0	15
175	The European network for care of children with paediatric rheumatic diseases: care across borders. <i>Rheumatology</i> , 2019, 58, 1188-1195.	0.9	15
176	American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 579-590.	1.5	15
177	Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. <i>Pediatric Rheumatology</i> , 2020, 18, 19.	0.9	15
178	Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021, 60, 4495-4507.	0.9	15
179	Toward the Development of New Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. <i>Annals of Paediatric Rheumatology</i> , 2012, 1, 1.	0.0	15
180	Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry. <i>Journal of Rheumatology</i> , 2022, 49, 398-407.	1.0	15

#	ARTICLE	IF	CITATIONS
181	Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases. <i>Archives of Disease in Childhood</i> , 2012, 97, 561-563.	1.0	14
182	The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. <i>Pediatric Rheumatology</i> , 2019, 17, 24.	0.9	14
183	A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021, 60, 2896-2905.	0.9	14
184	The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist. <i>Arthritis and Rheumatology</i> , 2022, 74, 1102-1121.	2.9	14
185	Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 1117-1126.	1.0	13
186	Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 162-170.	0.5	13
187	Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. <i>RMD Open</i> , 2020, 6, e001208.	1.8	13
188	Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. <i>Paediatric Drugs</i> , 2020, 22, 653-672.	1.3	13
189	Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use. <i>Rheumatology</i> , 2021, , .	0.9	13
190	Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1503-1509.	0.5	12
191	A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1540-1550.	2.9	11
192	Extrapolation or controlled trials in paediatrics: the current dilemma. <i>Archives of Disease in Childhood</i> , 2017, 102, 949-951.	1.0	10
193	Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. <i>Rheumatology</i> , 2019, 58, 1196-1205.	0.9	10
194	Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. <i>RMD Open</i> , 2021, 7, e001747.	1.8	10
195	Frequency of Radiographic Damage and Progression in Individual Joints in Children With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 27-33.	1.5	9
196	A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study. <i>Arthritis and Rheumatology</i> , 2014, 66, S8-S9.	2.9	9
197	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 319-327.	0.5	9
198	Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial. <i>Journal of Rheumatology</i> , 2018, 45, 1173-1179.	1.0	9

#	ARTICLE	IF	CITATIONS
199	Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries. <i>Rheumatology</i> , 2022, 61, 2524-2534.	0.9	9
200	The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 43-49.	1.5	8
201	The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 35-42.	1.5	8
202	The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 267-274.	1.5	8
203	Towards European harmonisation of healthcare for patients with rare immune disorders: outcome from the ERN RITA registries survey. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 33.	1.2	8
204	Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group. <i>Pediatric Research</i> , 2022, 91, 1069-1077.	1.1	8
205	The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 75-82.	1.5	7
206	Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study. <i>Arthritis Care and Research</i> , 2020, 72, 265-273.	1.5	7
207	Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. <i>Arthritis Research and Therapy</i> , 2020, 22, 211.	1.6	7
208	The impact of the Eurofever criteria and the new InFever MEFV classification in real life: Results from a large international FMF cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151957.	1.6	7
209	Classification Criteria and Diagnostic Tests for Vasculitides. <i>Journal of Rheumatology</i> , 2012, 39, 1503-1505.	1.0	6
210	Preface. <i>Rheumatology International</i> , 2018, 38, 1-3.	1.5	6
211	The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 155-161.	1.5	6
212	Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization. <i>World Journal of Pediatrics</i> , 2008, 4, 186-191.	0.8	5
213	A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, S23-S24.	2.9	5
214	The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 403-409.	1.5	5
215	The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 299-306.	1.5	5
216	Outcome Scores in Pediatric Rheumatology. <i>Current Rheumatology Reports</i> , 2021, 23, 23.	2.1	5

#	ARTICLE	IF	CITATIONS
217	A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH. <i>Arthritis and Rheumatology</i> , 2014, 66, S17-S18.	2.9	4
218	A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study. <i>Arthritis and Rheumatology</i> , 2014, 66, S80-S81.	2.9	4
219	A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH. <i>Arthritis and Rheumatology</i> , 2014, 66, S5-S6.	2.9	4
220	The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 395-402.	1.5	4
221	The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 27-33.	1.5	4
222	Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2020, 73, 1264-1274.	1.5	4
223	Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis. <i>Journal of Rheumatology</i> , 2021, 48, 898-906.	1.0	4
224	Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3218-3220.e1.	2.0	4
225	Performing trials in children with rheumatic diseases: Comment on the editorial by Lehman. <i>Arthritis and Rheumatism</i> , 2008, 58, 1201-1202.	6.7	3
226	The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 67-73.	1.5	3
227	Determinants of discordance between criteria for inactive disease and low disease activity in juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2020, 73, 1722-1729.	1.5	3
228	Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1073-1081.	1.0	3
229	Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 424-33.	0.4	3
230	Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis. <i>RMD Open</i> , 2022, 8, e002042.	1.8	3
231	A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From the TENDER Trial. <i>Arthritis and Rheumatology</i> , 2014, 66, S96.	2.9	2
232	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 251-258.	1.5	2
233	The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 19-26.	1.5	2
234	The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 211-218.	1.5	2

#	ARTICLE	IF	CITATIONS
235	The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 139-146.	1.5	2
236	Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2019, 17, 64.	0.9	2
237	FRI0181â€¦THE PLUTO STUDY: INTRAVENOUS BELIMUMAB IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		2
238	â€œTo Randomize, or Not to Randomize, That is the Questionâ€• <i>Arthritis and Rheumatology</i> , 2021, 73, 1776-1779.	2.9	2
239	Validity and reliability of four parent/patient reported outcome measures for juvenile idiopathic arthritis remote monitoring. <i>Arthritis Care and Research</i> , 2022, , .	1.5	2
240	Reply to letter by Isenberg and Gordon commenting on the Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 3723-3724.	6.7	1
241	Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries. <i>Pediatric Rheumatology</i> , 2014, 12, .	0.9	1
242	A30: Assessment of Construct and Discriminative Validity of the 3-Variable JADAS in Relation of Parent-Reported Outcomes. <i>Arthritis and Rheumatology</i> , 2014, 66, S46-S46.	2.9	1
243	The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 235-242.	1.5	1
244	The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 387-393.	1.5	1
245	The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 243-250.	1.5	1
246	The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 83-90.	1.5	1
247	The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 219-226.	1.5	1
248	The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 171-178.	1.5	1
249	THU0666â€¦SERIOUS/AT LEAST MODERATE INFECTIONS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS ON SYNTHETIC AND BIOLOGIC DRUGS FROM THE PHARMACHILD REGISTRY. , 2019, , .		1
250	FRI0547â€¦DEVELOPMENT AND INITIAL VALIDATION OF THE SYSTEMIC JADAS, A NEW COMPOSITE DISEASE ACTIVITY SCORE FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		1
251	Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis?. <i>Pediatric Rheumatology</i> , 2014, 12, .	0.9	0
252	Dissecting the heterogeneity of macrophage activation syndrome. <i>Pediatric Rheumatology</i> , 2014, 12, .	0.9	0

#	ARTICLE	IF	CITATIONS
253	A171: Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight. <i>Arthritis and Rheumatology</i> , 2014, 66, S222.	2.9	0
254	A169: Cumulative Long-Term Safety, Efficacy and Patient-Reported Outcomes in Children With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept: Up to 7 Years of Treatment. <i>Arthritis and Rheumatology</i> , 2014, 66, S218-S219.	2.9	0
255	Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients. <i>Pediatric Rheumatology</i> , 2014, 12, .	0.9	0
256	The PRINTO juvenile dermatomyositis trial – Authors' reply. <i>Lancet</i> , The, 2016, 387, 2601.	6.3	0
257	Trial Design and Collaborative Work in Pediatric Rheumatology. , 2017, , 47-54.		0
258	The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 59-66.	1.5	0
259	The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 51-58.	1.5	0
260	The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 227-233.	1.5	0
261	The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 363-369.	1.5	0
262	The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 107-113.	1.5	0
263	The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 283-289.	1.5	0
264	The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 99-105.	1.5	0
265	The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 275-282.	1.5	0
266	The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 347-354.	1.5	0
267	The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 371-377.	1.5	0
268	The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 187-194.	1.5	0
269	The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 115-122.	1.5	0
270	The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 147-153.	1.5	0



#	ARTICLE	IF	CITATIONS
271	The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 179-186.	1.5	0
272	The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 291-298.	1.5	0
273	The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 307-313.	1.5	0
274	The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 315-321.	1.5	0
275	The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 331-338.	1.5	0
276	The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 91-98.	1.5	0
277	The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 131-138.	1.5	0
278	The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 163-169.	1.5	0
279	The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 195-201.	1.5	0
280	The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 203-209.	1.5	0
281	The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 259-265.	1.5	0
282	The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 355-361.	1.5	0
283	The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 379-386.	1.5	0
284	The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 323-329.	1.5	0
285	The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 123-130.	1.5	0
286	The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 339-346.	1.5	0
287	AB1072Bâ€¦THE CONSEQUENCES OF THE PROVISIONAL PAEDIATRIC RHEUMATOLOGY INTERNATIONAL TRIALS ORGANISATION JUVENILE IDIOPATHIC ARTHRITIS CLASSIFICATION CRITERIA. , 2019, , .		0
288	OP0056â€¦MAINTENANCE OF CLINICAL RESPONSE IN INDIVIDUAL CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH SUBCUTANEOUS ABATACEPT. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
289	FRI0572â€¦DISABILITY AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL. , 2019, , .		0
290	FRI0571â€¦MEASUREMENT PERFORMANCE OF REDUCED VERSIONS OF MUSCLE STRENGTH TOOLS IN JUVENILE DERMATOMYOSITIS. , 2019, , .		0
291	FRI0537â€¦LONG-TERM OUTCOMES AND TREATMENT EFFICACY IN PATIENTS WITH TNF RECEPTOR-ASSOCIATED AUTOINFLAMMATORY SYNDROME (TRAPS): A SERIES OF 290 CASES FROM THE EUROFEVER/EUROTRAPS INTERNATIONAL REGISTRY. , 2019, , .		0
292	OPO058â€¦DEVELOPMENT OF INFLAMMATORY BOWEL DISEASE DURING TREATMENT WITH ETANERCEPT IN PATIENTSWITH JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0
293	FRI0543â€¦EFFICACY AND SAFETY OF INTRAVENOUS GOLIMUMAB IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM A PHASE 3 OPEN-LABEL STUDY. , 2019, , .		0
294	THU0517â€¦THE LONGITUDINAL EUROFEVER PROJECT: AN UPDATE ON ENROLLMENT. , 2019, , .		0
295	OPO258â€¦LESSON FROM EUROFEVER REGISTRY AFTER THE FIRST TEN YEARS OF ENROLLMENT. , 2019, , .		0
296	THU0516â€¦LONG-TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB ADMINISTRATION IN SYSTEMIC AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0
297	THU0515â€¦PAIN IS THE MAIN DETERMINANT OF WELL-BEING IN OLIGO- AND POLYARTICULAR JIA: EVIDENCE FROM THE PHARMACHILD REGISTRY. , 2019, , .		0
298	SP0021â€¦DELIVERING FUTURE GLOBAL RESEARCH CHALLENGES IN PAEDIATRIC RHEUMATOLOGY. , 2019, , .		0
299	Some clarifications on the new classification criteria for recurrent fevers. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1550-1551.	1.6	0
300	Response to: â€˜Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?â€™™ by Fayand et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2019-216862.	0.5	0
301	Biologic Response Modifiers in Pediatric Rheumatology. , 2017, , 77-87.		0
302	Reply. <i>Arthritis and Rheumatology</i> , 2022, 74, 913-914.	2.9	0
303	Tofacitinib for juvenile idiopathic arthritis â€œ Authors' reply. <i>Lancet, The</i> , 2022, 399, 1866.	6.3	0